PARABON NANOLABS, INC. — Department of Health and Human Services SBIR Phase I: NIA

Description

DESCRIPTION provided by applicant Late onset Alzheimerandapos s Disease LOAD affects millions of elderly people in the United States yet there are no well established clinical guidelines for assessing a personandapos s relative risk Accurate assessment of lifetime risk for LOAD would give high risk individuals the opportunity to undergo regular biomarker screening for signs of disease and to modify environmental risk factors or participate in prospective clinical trials This Phase I SBIR project aims to develop a risk prediction model for LOAD that meets or exceeds the accuracy standards established in by the Working Group for Biochemical and Molecular Markers of Alzheimerandapos s Disease The recent release of whole genome sequence data from an extensively phenotyped cohort of the Alzheimerandapos s Disease Neuroimaging Initiative creates a unique opportunity to develop the methodology needed to successfully construct such a risk prediction model The Parabon team will undertake three specific aims in pursuit of the final goal of producing a risk prediction model that can be used in the clinic First a novel methodology will be created for analyzing whole genome sequence data to discover common SNPs rare variants and epistatic interactions that significantly associate with LOAD endophenotypes the specific physiological changes that underlie disease This will require innovative algorithm and software development particularly the implementation of multi objective optimization in our existing evolutionary search algorithm for detecting epistasis Second the discovered significant variants will be built into risk prediction models for each endophenotype using state of the art machine learning methods These models will then be combined into a single predictive model for lifetime risk which will be validated in an independent cohort from the Alzheimerandapos s Disease Sequencing Project Finally to quantify the confidence associated with each prediction made by the model algorithms and software for calculating confidence intervals will be developed and implemented Each new prediction will be presented with a measure of confidence to enable clinicians to determine what if any intervention is necessary When these aims have been completed Parabon will have produced the first clinically relevant genetic risk prediction model for late onset Alzheimerandapos s Disease as well as a suite of software that can be used in the development of other diagnostics In Phase II we will move beyond the ADNI supplied endophenotypes using image processing and deep learning to infer neuroimaging features most relevant to AD diagnoses as well as work to validate the predictive models in a larger more diverse cohort across multiple sites PUBLIC HEALTH RELEVANCE This Phase I SBIR aims to develop a highly accurate predictive model for lifetime risk of late onset Alzheimerandapos s Disease to enable early identification of high risk individuals for participation in clinical trials and regular screening for signs of disease In pursuit of this goal the Parabon team will develop algorithms and software to build a novel methodology for the analysis of whole genome sequence data and endophenotype measures from the Alzheimerandapos s Disease Neuroimaging Initiative This project will produce the first clinically relevant risk prediction model for late onset Alzheimerandapos s Disease and a suite of software that can be used for the production of diagnostics for other diseases